Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Natural History of Human Epidermal Growth Factor Receptor 2–Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice

Natural History of Human Epidermal Growth Factor Receptor 2–Amplified and Human Epidermal Growth... PURPOSEThe molecular heterogeneity of metastatic colorectal cancer (mCRC) presents a therapeutic challenge, with few trials focused on patients with human epidermal growth factor receptor 2 amplification (HER2-Amp). Our limited understanding of real-world patterns and outcomes by HER2 status of treatment-refractory patients leaves treatment decisions with little contextual information. We conducted a retrospective cohort study to describe the natural disease history of patients with refractory mCRC using an electronic health record–derived database with oncogenomic information.METHODSWe included patients with stage IV or recurrent mCRC diagnosed from January 2011 through December 2019 from a deidentified clinicogenomic database. Patients with ≥ 2 documented clinic visits, ≥ 2 lines of therapy (LOT) after mCRC diagnosis, and comprehensive genomic profiling were eligible. Patient records defined by treatment-refractory LOT were allocated to the HER2-Amp or HER2 wild-type (WT) cohort on the basis of comprehensive genomic profiling. Index date was defined as the start of any treatment-refractory LOT (≥ 2 LOT; patients could contribute multiple records). Descriptive statistics included demographic and clinical characteristics, treatments, laboratory values, and biomarkers. Overall survival (OS) was calculated as time (in months) from the index date until death from any cause and analyzed using Kaplan-Meier methodology. Sensitivity analyses were conducted to test the robustness of the primary findings.RESULTSA total of 576 patients were included (1,339 records); 63 (158 records) were HER2-Amp, and 513 (1,181 records) were HER2-WT. Demographics, clinical characteristics, biomarkers, and laboratory values were comparable between HER2 cohorts. OS was similar, with an unadjusted median OS of 11.2 months (95% CI, 8.6 to 15.1) and 9.9 months (95% CI, 8.3 to 10.9) across LOT for HER2-Amp and HER2-WT cohorts, respectively.CONCLUSIONThis study showed considerable treatment heterogeneity and poor outcomes among patients with treatment-refractory mCRC, emphasizing a substantial unmet therapeutic need. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JCO: Clinical Cancer Informatics Wolters Kluwer Health

Natural History of Human Epidermal Growth Factor Receptor 2–Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice

Download PDF
11 pages

Loading next page...
 
/lp/wolters-kluwer-health/natural-history-of-human-epidermal-growth-factor-receptor-2-amplified-Rr5dc7Jx1V
Publisher
Wolters Kluwer Health
Copyright
© 2022 by American Society of Clinical Oncology
eISSN
2473-4276
DOI
10.1200/cci.21.00133
Publisher site
See Article on Publisher Site

Abstract

PURPOSEThe molecular heterogeneity of metastatic colorectal cancer (mCRC) presents a therapeutic challenge, with few trials focused on patients with human epidermal growth factor receptor 2 amplification (HER2-Amp). Our limited understanding of real-world patterns and outcomes by HER2 status of treatment-refractory patients leaves treatment decisions with little contextual information. We conducted a retrospective cohort study to describe the natural disease history of patients with refractory mCRC using an electronic health record–derived database with oncogenomic information.METHODSWe included patients with stage IV or recurrent mCRC diagnosed from January 2011 through December 2019 from a deidentified clinicogenomic database. Patients with ≥ 2 documented clinic visits, ≥ 2 lines of therapy (LOT) after mCRC diagnosis, and comprehensive genomic profiling were eligible. Patient records defined by treatment-refractory LOT were allocated to the HER2-Amp or HER2 wild-type (WT) cohort on the basis of comprehensive genomic profiling. Index date was defined as the start of any treatment-refractory LOT (≥ 2 LOT; patients could contribute multiple records). Descriptive statistics included demographic and clinical characteristics, treatments, laboratory values, and biomarkers. Overall survival (OS) was calculated as time (in months) from the index date until death from any cause and analyzed using Kaplan-Meier methodology. Sensitivity analyses were conducted to test the robustness of the primary findings.RESULTSA total of 576 patients were included (1,339 records); 63 (158 records) were HER2-Amp, and 513 (1,181 records) were HER2-WT. Demographics, clinical characteristics, biomarkers, and laboratory values were comparable between HER2 cohorts. OS was similar, with an unadjusted median OS of 11.2 months (95% CI, 8.6 to 15.1) and 9.9 months (95% CI, 8.3 to 10.9) across LOT for HER2-Amp and HER2-WT cohorts, respectively.CONCLUSIONThis study showed considerable treatment heterogeneity and poor outcomes among patients with treatment-refractory mCRC, emphasizing a substantial unmet therapeutic need.

Journal

JCO: Clinical Cancer Informatics – Wolters Kluwer Health

Published: Mar 21, 2022

References

  • Global patterns and trends in colorectal cancer incidence and mortality
    Arnold, M; Sierra, MS; Laversanne, M
  • The consensus molecular subtypes of colorectal cancer
    Guinney, J; Dienstmann, R; Wang, X
  • Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
    Hsu, H-C; Thiam, TK; Lu, Y-J
  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
    De Roock, W; Claes, B; Bernasconi, D
  • HERS2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer
    Singh, RKP; Overman, MJ; Yu, R
  • Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
    Ross, JS; Fakih, M; Ali, SM
  • HER2: An emerging target in colorectal cancer
    Greally, M; Kelly, CM; Cerecek, A
  • Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial
    Sartore-Bianchi, A; Lonardi, S; Martino, C
  • Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: An updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study
    Meric-Bernstam, F; Hurwitz, H; Singh, RKP
  • Building external control arms from patient-level electronic health record data to replicate the randomized IMblaze370 control arm in metastatic colorectal cancer
    Schröder, C; Lawrance, M; Li, C
  • Association of patient characteristics and tumor genetics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database
    Singal, G; Miller, PG; Agarwala, V
  • Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
    Frampton, GM; Fichtenholtz, A; Otto, GA
  • How to choose a time zero for patients in external control arms
    Backenroth, D
  • Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States
    Zhang, Q; Gossai, A; Monroe, S
  • Comprehensive molecular characterization of human colon and rectal cancer
  • HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
    Richman, SD; Southward, K; Chambers, P
  • ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)
    Laurent-Puig, P; Balogoun, R; Cayre, A
  • Frequency of HER-2 positivity in rectal cancer and prognosis
    Conradi, LC; Styczen, H; Sprenger, T
  • HER-2/neu overexpression is an independent prognostic factor in colorectal cancer
    Park, DI; Kang, MS; Oh, SJ
  • The p38 MAPK signaling activation in colorectal cancer upon therapeutic treatments
    Pranteda, A; Piastra, V; Stramucci, L